Elite Pharmaceuticals (OTCMKTS:ELTP) Stock Price Passes Above 50 Day Moving Average – Should You Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTPGet Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.36 and traded as high as $0.37. Elite Pharmaceuticals shares last traded at $0.3690, with a volume of 252,282 shares.

Elite Pharmaceuticals Stock Performance

The company has a quick ratio of 5.22, a current ratio of 6.45 and a debt-to-equity ratio of 0.04. The company has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.40. The stock has a market capitalization of $397.16 million, a price-to-earnings ratio of 18.44 and a beta of 0.39.

About Elite Pharmaceuticals

(Get Free Report)

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

Featured Stories

Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.